प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
Allogene ने cema-cel के लिए ALPHA3 की सकारात्मक अंतरिम फ्यूटिलिटी डेटा रिपोर्ट की
The 8-K discloses the first interim futility analysis from the pivotal Phase 2 ALPHA3 trial of cema-cel in 1L LBCL consolidation. MRD negativity was achieved in 58.3% of cema-cel-treated patients versus 16.7% in the observation arm, with rapid ctDNA clearance and no CRS, ICANS, or GvHD reported. The trial continues blinded for EFS, PFS, and OS endpoints, with full enrollment expected by end-2027 and an interim EFS analysis planned for mid-2027.
मुख्य तथ्य
- फाइल किया गया
- 13 अप्रैल 2026, 11:45 am
- घटना
- टॉपलाइन परिणाम
- दिशा
- सकारात्मक
- कंपनी
ALLOAllogene- संपत्ति
- cemacabtagene ansegedleucel
- स्रोत
- SEC 8-K
- विश्वसनीयता
- स्रोत सहित
- घटना-मुक्त उत्तरजीविता अंतरिम
- मध्य-2027
- घटना-मुक्त उत्तरजीविता प्राथमिक
- मध्य-2028
- सामुदायिक स्थल
- एक-तिहाई
- नामांकन लक्ष्य
- 220
- न्यूनतम अवशिष्ट रोग निकासी सेमा सेल
- 58.3% (7/12)
- सीटीडीएनए परिवर्तन अवलोकन
- +26.6%
- सीटीडीएनए कमी सेमा सेल
- 97.7%
- न्यूनतम अवशिष्ट रोग निकासी अवलोकन
- 16.7% (2/12)
स्रोत का अंश
8-K false 0001737287 0001737287 2026-04-13 2026-04-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 Allogene Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38693 82-3562771 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 210 East Grand Avenue South San Francisco , CA 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (650) 457-2700 N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Fo